These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

573 related articles for article (PubMed ID: 25155442)

  • 21. The use of agalsidase alfa enzyme replacement therapy in the treatment of Fabry disease.
    Morel CF; Clarke JT
    Expert Opin Biol Ther; 2009 May; 9(5):631-9. PubMed ID: 19368525
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Enzyme replacement therapy stabilizes obstructive pulmonary Fabry disease associated with respiratory globotriaosylceramide storage.
    Wang RY; Abe JT; Cohen AH; Wilcox WR
    J Inherit Metab Dis; 2008 Dec; 31 Suppl 2():S369-74. PubMed ID: 18937048
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Agalsidase-β should be proposed as first line therapy in classic male Fabry patients with undetectable α-galactosidase A activity.
    Nowak A; Dormond O; Monzambani V; Huynh-Do U; Barbey F
    Mol Genet Metab; 2022; 137(1-2):173-178. PubMed ID: 36087505
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enzyme replacement therapy in heterozygous females with Fabry disease: results of a phase IIIB study.
    Baehner F; Kampmann C; Whybra C; Miebach E; Wiethoff CM; Beck M
    J Inherit Metab Dis; 2003; 26(7):617-27. PubMed ID: 14707510
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical efficacy of enzyme replacement therapy in Fabry disease. A critical review].
    Lidove O; Papo T
    Rev Med Interne; 2009 Oct; 30(10):920-9. PubMed ID: 19524334
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fabry disease in children and the effects of enzyme replacement treatment.
    Pintos-Morell G; Beck M
    Eur J Pediatr; 2009 Nov; 168(11):1355-63. PubMed ID: 19242721
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enzyme replacement therapy in Fabry disease: influence on cardiac manifestations.
    Caballero L; Climent V; Hernández-Romero D; Quintanilla MA; de la Morena G; Marín F
    Curr Med Chem; 2010; 17(16):1679-89. PubMed ID: 20345350
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reduced alpha-Gal A enzyme activity in Fabry fibroblast cells and Fabry mice tissues induced by serum from antibody positive patients with Fabry disease.
    Ohashi T; Iizuka S; Ida H; Eto Y
    Mol Genet Metab; 2008 Jul; 94(3):313-8. PubMed ID: 18456533
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Update on role of agalsidase alfa in management of Fabry disease.
    Ramaswami U
    Drug Des Devel Ther; 2011 Mar; 5():155-73. PubMed ID: 21552486
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of enzyme replacement therapy on pain and health related quality of life in patients with Fabry disease: data from FOS (Fabry Outcome Survey).
    Hoffmann B; Garcia de Lorenzo A; Mehta A; Beck M; Widmer U; Ricci R;
    J Med Genet; 2005 Mar; 42(3):247-52. PubMed ID: 15744039
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prediction of improved therapeutics for fabry disease patients generated by mutagenesis of the α-galactosidase A active site, dimer interface, and glycosylation region.
    Stokes ES; Gilchrist ML; Calhoun DH
    Protein Expr Purif; 2020 Nov; 175():105710. PubMed ID: 32738442
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Oral Migalastat HCl Leads to Greater Systemic Exposure and Tissue Levels of Active α-Galactosidase A in Fabry Patients when Co-Administered with Infused Agalsidase.
    Warnock DG; Bichet DG; Holida M; Goker-Alpan O; Nicholls K; Thomas M; Eyskens F; Shankar S; Adera M; Sitaraman S; Khanna R; Flanagan JJ; Wustman BA; Barth J; Barlow C; Valenzano KJ; Lockhart DJ; Boudes P; Johnson FK
    PLoS One; 2015; 10(8):e0134341. PubMed ID: 26252393
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enzyme replacement therapy in Fabry's disease: recent advances and clinical applications.
    Mignani R; Cagnoli L
    J Nephrol; 2004; 17(3):354-63. PubMed ID: 15365954
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of a Biosimilar of Agalsidase Beta for the Treatment of Fabry Disease: Preclinical Evaluation.
    van Kuilenburg ABP; Hollak CEM; Travella A; Jacobs M; Gentilini LD; Leen R; der Vlugt KMMG; Stet FSB; Goorden SMI; van der Veen S; Criscuolo M; Papouchado M
    Drugs R D; 2023 Jun; 23(2):141-153. PubMed ID: 37083901
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Substrate reduction augments the efficacy of enzyme therapy in a mouse model of Fabry disease.
    Marshall J; Ashe KM; Bangari D; McEachern K; Chuang WL; Pacheco J; Copeland DP; Desnick RJ; Shayman JA; Scheule RK; Cheng SH
    PLoS One; 2010 Nov; 5(11):e15033. PubMed ID: 21124789
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Enzyme replacement therapy with agalsidase beta in kidney transplant patients with Fabry disease: a pilot study.
    Mignani R; Panichi V; Giudicissi A; Taccola D; Boscaro F; Feletti C; Moneti G; Cagnoli L
    Kidney Int; 2004 Apr; 65(4):1381-5. PubMed ID: 15086478
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A detailed pathologic examination of heart tissue from three older patients with Anderson-Fabry disease on enzyme replacement therapy.
    Sheppard MN; Cane P; Florio R; Kavantzas N; Close L; Shah J; Lee P; Elliott P
    Cardiovasc Pathol; 2010; 19(5):293-301. PubMed ID: 19631563
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Agalsidase Beta: a review of its use in the management of Fabry disease.
    Keating GM; Simpson D
    Drugs; 2007; 67(3):435-55. PubMed ID: 17335299
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Enzyme replacement therapy partially prevents invariant Natural Killer T cell deficiency in the Fabry disease mouse model.
    Macedo MF; Quinta R; Pereira CS; Sa Miranda MC
    Mol Genet Metab; 2012 May; 106(1):83-91. PubMed ID: 22425450
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Fabry disease in Spain: first analysis of the response to enzyme replacement therapy].
    Rivera Gallego A; López Rodríguez M; Barbado Hernández FJ; Barba Romero MA; García de Lorenzo Y Mateos A; Pintos Morelle G;
    Med Clin (Barc); 2006 Oct; 127(13):481-4. PubMed ID: 17043001
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.